All News
ICYMI: Protective Benefit of Colchicine in COVID-19 Infection
Colchicine has been advocated as a potential anti-inflammatory intervention in patients with the coronavirus 2 infection and clinical trials have been developed to assess its effect in early COVID-2 infection. JAMA has published a randomized clinical trial showing that low dose colchicine had less clinical deterioration without significant changes in biomarkers, such as high-sensitivity cardiac troponin and C-reactive protein.
Read ArticleICYMI: Preventing COVID - Masks, Meters and Eyewear
A Lancet systematic review and meta-analysis provides the basis for physical distancing and the value of making as measures to prevent infection with coronavirus 2 (SARS-CoV-2) or COVID-19.
The analysis included 172 observational studies, no randomised controlled trials and 44 relevant comparative studies involving 25 697 patients.
ICYMI: COVID-19 and Thrombotic Complications
Severe and fatal outcomes with coronavirus infection are often the result of the downstream damage that follows the viral infection. Rising high on the list of complications are the hematologic and vascular complications seen in severely affected patients, so much so that many centers are routinely anticoagulating hospitalized (but not ambulatory) COVID patients.
Read ArticleICYMI: The Nine Lives of Hydroxychloroquine (Updated)
Hydroxychloroquine is one of many medications frequently used in rheumatology practice. Its remarkable versatility is attested by its routine use in lupus, in patients with an autoimmune coagulopathy, in patients with rheumatoid arthritis, as well as in those with a low-level inflammatory arthropathy.
Read Article
Links:
Dr. John Cush RheumNow ( View Tweet)

Links:
Dr. John Cush RheumNow ( View Tweet)


Links:
Dr. John Cush RheumNow ( View Tweet)

Links:
Dr. John Cush RheumNow ( View Tweet)

Links:
Dr. John Cush RheumNow ( View Tweet)

Links:
Dr. John Cush RheumNow ( View Tweet)

Links:
Dr. John Cush RheumNow ( View Tweet)

Dr. John Cush RheumNow ( View Tweet)

Links:
Dr. John Cush RheumNow ( View Tweet)

Dr. John Cush RheumNow ( View Tweet)

Links:
Dr. John Cush RheumNow ( View Tweet)

Dr. John Cush RheumNow ( View Tweet)


Links:
Dr. John Cush RheumNow ( View Tweet)
